DOYLESTOWN, Pa.--(BUSINESS WIRE)--Incite Health, Inc. applauds Governor Shapiro’s signing of House Bill 1754 into law. This pivotal legislation will transform healthcare for Pennsylvanians by mandating comprehensive biomarker testing coverage by all state-regulated health plans, including Medicaid, ensuring more residents will benefit from precision medicine.
“Governor Shapiro’s commitment to healthcare innovation and patient advocacy is evident in this landmark decision,” said Renold J. Capocasale, Chief Executive Officer of Incite Health. “By enabling wider access to biomarker testing, we are paving the way for targeted treatments that not only improve survival rates and quality of life but can also reduce healthcare costs for patients facing serious illnesses such as cancer or other chronic diseases.”
The importance of biomarker testing in modern healthcare cannot be overstated. It facilitates personalized care by matching patients with the most effective treatments and at the right dose based on their unique genetic makeup. Despite its proven benefits, insurance coverage for biomarker testing has lagged, often leaving patients with the difficult choice of paying out-of-pocket or forgoing potentially life-saving testing. House Bill 1754 addresses these disparities, particularly benefiting communities of color, lower-income individuals, and rural populations who have been disproportionately affected by limited access.
“The PA Biotech Center plays a crucial role in our region,” said PA State Senator Steve Santarsiero. He added, “Significant advancements are consistently emerging from this center, Incite Health, and the innovative work they are doing is a perfect example. Their work will significantly improve healthcare. I am pleased to have backed legislation that ensures medical coverage keeps pace with this technological advancement, ultimately enhancing the quality of life for many.”
Donna Greco, Government Relations Director for the American Cancer Society Cancer Action Network (ACS CAN) in Pennsylvania, praised the legislation, stating, “With his signature, Governor Shapiro has delivered hope to countless Pennsylvanians who will benefit from biomarker testing. This game-changing bill is good for Pennsylvania, the health of our state and its residents.”
Christopher Molineaux, President and Chief Executive Officer of LSPA said, “As the state association that represents organizations involved in creating precision medicines and diagnostics, and the patient advocacy groups those entities serve, this legislation was of great interest. Life Sciences PA was proud to be part of the Pennsylvania Biomarker Testing Coalition and to support the legislation that expands access to biomarker testing to help determine the treatment most effective for a specific patient.”
Incite Health remains dedicated to advancing healthcare access and delivering healthcare innovation. We believe that the implementation of House Bill 1754 will not only improve health outcomes but also set a new standard for patient care in Pennsylvania and beyond. For more information on precision medicine and biomarker testing, visit www.fightcancer.org/biomarkers and https://incitehealth.com/pharmacogenomics-testing/
About Incite Health:
Incite Health is a leading CLIA-certified, CAP-accredited high complexity laboratory dedicated to revolutionizing clinical decision making and enhancing patient care through innovative medical practices and technologies. The company offers diagnostics, precision medicine solutions and consultative services to improve health outcomes and quality of life for all patients. Incite Health clients include Pharmaceutical & Biotech clinical trial sponsors, Contract Research Organizations, Health Care Professionals, Long Term Care Facilities and privately insured employers.
